Cargando…

308. Injectable Scaffold-based Vaccination For Prevention of Periprosthetic Joint Infection

BACKGROUND: There are currently no vaccines available to prevent periprosthetic joint infection (PJI) and existing vaccine platforms have failed against Staphylococcus aureus in clinical trials. We have developed a novel injectable scaffold-based vaccine for PJI. In this study, we evaluated vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatara, Alexander M, Lightbown, Shanda, Ijaz, Hamza, Super, Michael, Nelson, Sandra B, Mooney, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678120/
http://dx.doi.org/10.1093/ofid/ofad500.380
_version_ 1785150290329075712
author Tatara, Alexander M
Lightbown, Shanda
Ijaz, Hamza
Super, Michael
Nelson, Sandra B
Mooney, David
author_facet Tatara, Alexander M
Lightbown, Shanda
Ijaz, Hamza
Super, Michael
Nelson, Sandra B
Mooney, David
author_sort Tatara, Alexander M
collection PubMed
description BACKGROUND: There are currently no vaccines available to prevent periprosthetic joint infection (PJI) and existing vaccine platforms have failed against Staphylococcus aureus in clinical trials. We have developed a novel injectable scaffold-based vaccine for PJI. In this study, we evaluated vaccine immune response and bacterial burden in a murine model of PJI. METHODS: Vaccines consisting of mesoporous silica rods (scaffold) and demethylated CpG (adjuvant) were prepared using S. aureus-derived pathogen-associated molecular patterns (PAMPs) as described previously (Super and Doherty et al., Nat Biomed Eng 2022). Mice were either unvaccinated or vaccinated by subcutaneous scaffold injection containing different amounts of PAMP antigen: 7.5, 30, or 150 units (n=5-8 per group). Mice received a second scaffold injection on Day 14 (same dose as Day 0) as booster. Sera was collected on Day 28. For a challenge study, mice vaccinated on Days 0 and 14 with scaffold loaded with 30 U of PAMPs (“Vaccinated”) underwent implantation of a stainless-steel wire in the distal femur protruding into the joint space on Day 35 (n=8). The implant was inoculated with 1000 CFU S. aureus Xen29, a bioluminescent strain. Infected mice without vaccination (“Unvaccinated”) and without infection (“Uninfected”) also underwent implant insertion (n=5). Mice underwent bioluminescent imaging, collection of sera and tissue, and euthanasia with implant harvest on Day 49. RESULTS: Vaccination increased anti-S. aureus antibodies in a dose-dependent manner. Vaccination with Xen29 PAMPs resulted in antibodies with cross-reactivity against other S. aureus strains (RN4220, RN4220ΔSpa, and BAA1717). Vaccinated mice had increased CD4+ and CD8+ T cells in the adjacent draining lymph node. Vaccination induced higher IgG1 and IgG2b whereas infection only increased IgG2b (Fig. 1A). Vaccinated animals had bioluminescent similar to uninfected animals by Day 45 (Fig. 1B). Vaccinated animals had significantly less implant bacteria than unvaccinated animals and 25% of vaccinated animals did not have any detectable bacteria at euthanasia (Fig. 1C). [Figure: see text] CONCLUSION: Scaffold-based vaccination increased generalized anti-S. aureus antibody production in an antigen dose-dependent manner and decreased bacterial burden in a murine model of PJI. DISCLOSURES: David Mooney, Ph.D., Advanced Healthcare Materials: Board Member|Agnovos: Stocks/Bonds|Attivare: Stocks/Bonds|Boston Scientific: Advisor/Consultant|Cartesian Therapeutics: Advisor/Consultant|IVIVA: Stocks/Bonds|Johnson & Johnson: Advisor/Consultant|Journal of Biomedical Materials Research: Board Member|Lightning Bio: Stocks/Bonds|Lyell: Stocks/Bonds|Medicenna: Advisor/Consultant|Norvartis: Advisor/Consultant|Norvartis: Grant/Research Support|Norvartis: IP Royalties|Revela: Stocks/Bonds|Samyang: Advisor/Consultant
format Online
Article
Text
id pubmed-10678120
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106781202023-11-27 308. Injectable Scaffold-based Vaccination For Prevention of Periprosthetic Joint Infection Tatara, Alexander M Lightbown, Shanda Ijaz, Hamza Super, Michael Nelson, Sandra B Mooney, David Open Forum Infect Dis Abstract BACKGROUND: There are currently no vaccines available to prevent periprosthetic joint infection (PJI) and existing vaccine platforms have failed against Staphylococcus aureus in clinical trials. We have developed a novel injectable scaffold-based vaccine for PJI. In this study, we evaluated vaccine immune response and bacterial burden in a murine model of PJI. METHODS: Vaccines consisting of mesoporous silica rods (scaffold) and demethylated CpG (adjuvant) were prepared using S. aureus-derived pathogen-associated molecular patterns (PAMPs) as described previously (Super and Doherty et al., Nat Biomed Eng 2022). Mice were either unvaccinated or vaccinated by subcutaneous scaffold injection containing different amounts of PAMP antigen: 7.5, 30, or 150 units (n=5-8 per group). Mice received a second scaffold injection on Day 14 (same dose as Day 0) as booster. Sera was collected on Day 28. For a challenge study, mice vaccinated on Days 0 and 14 with scaffold loaded with 30 U of PAMPs (“Vaccinated”) underwent implantation of a stainless-steel wire in the distal femur protruding into the joint space on Day 35 (n=8). The implant was inoculated with 1000 CFU S. aureus Xen29, a bioluminescent strain. Infected mice without vaccination (“Unvaccinated”) and without infection (“Uninfected”) also underwent implant insertion (n=5). Mice underwent bioluminescent imaging, collection of sera and tissue, and euthanasia with implant harvest on Day 49. RESULTS: Vaccination increased anti-S. aureus antibodies in a dose-dependent manner. Vaccination with Xen29 PAMPs resulted in antibodies with cross-reactivity against other S. aureus strains (RN4220, RN4220ΔSpa, and BAA1717). Vaccinated mice had increased CD4+ and CD8+ T cells in the adjacent draining lymph node. Vaccination induced higher IgG1 and IgG2b whereas infection only increased IgG2b (Fig. 1A). Vaccinated animals had bioluminescent similar to uninfected animals by Day 45 (Fig. 1B). Vaccinated animals had significantly less implant bacteria than unvaccinated animals and 25% of vaccinated animals did not have any detectable bacteria at euthanasia (Fig. 1C). [Figure: see text] CONCLUSION: Scaffold-based vaccination increased generalized anti-S. aureus antibody production in an antigen dose-dependent manner and decreased bacterial burden in a murine model of PJI. DISCLOSURES: David Mooney, Ph.D., Advanced Healthcare Materials: Board Member|Agnovos: Stocks/Bonds|Attivare: Stocks/Bonds|Boston Scientific: Advisor/Consultant|Cartesian Therapeutics: Advisor/Consultant|IVIVA: Stocks/Bonds|Johnson & Johnson: Advisor/Consultant|Journal of Biomedical Materials Research: Board Member|Lightning Bio: Stocks/Bonds|Lyell: Stocks/Bonds|Medicenna: Advisor/Consultant|Norvartis: Advisor/Consultant|Norvartis: Grant/Research Support|Norvartis: IP Royalties|Revela: Stocks/Bonds|Samyang: Advisor/Consultant Oxford University Press 2023-11-27 /pmc/articles/PMC10678120/ http://dx.doi.org/10.1093/ofid/ofad500.380 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Tatara, Alexander M
Lightbown, Shanda
Ijaz, Hamza
Super, Michael
Nelson, Sandra B
Mooney, David
308. Injectable Scaffold-based Vaccination For Prevention of Periprosthetic Joint Infection
title 308. Injectable Scaffold-based Vaccination For Prevention of Periprosthetic Joint Infection
title_full 308. Injectable Scaffold-based Vaccination For Prevention of Periprosthetic Joint Infection
title_fullStr 308. Injectable Scaffold-based Vaccination For Prevention of Periprosthetic Joint Infection
title_full_unstemmed 308. Injectable Scaffold-based Vaccination For Prevention of Periprosthetic Joint Infection
title_short 308. Injectable Scaffold-based Vaccination For Prevention of Periprosthetic Joint Infection
title_sort 308. injectable scaffold-based vaccination for prevention of periprosthetic joint infection
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678120/
http://dx.doi.org/10.1093/ofid/ofad500.380
work_keys_str_mv AT tataraalexanderm 308injectablescaffoldbasedvaccinationforpreventionofperiprostheticjointinfection
AT lightbownshanda 308injectablescaffoldbasedvaccinationforpreventionofperiprostheticjointinfection
AT ijazhamza 308injectablescaffoldbasedvaccinationforpreventionofperiprostheticjointinfection
AT supermichael 308injectablescaffoldbasedvaccinationforpreventionofperiprostheticjointinfection
AT nelsonsandrab 308injectablescaffoldbasedvaccinationforpreventionofperiprostheticjointinfection
AT mooneydavid 308injectablescaffoldbasedvaccinationforpreventionofperiprostheticjointinfection